Physician profile
Jin Lee
NPI 1235591678
$1,580.82
in general payments reported to CMS, 2019-2025
10 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $46.71 · 2021: $264 · 2022: $59.91 · 2024: $275 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $701.85 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $188.08 | 2025 | Sapien 3 Ultra Resilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.12 | 2019-2022 | |
| Dexcom, INC. | $141.26 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Mallinckrodt Hospital Products INC. | $121.11 | 2025 | Terlivaz |
| Portola Pharmaceuticals, LLC | $104.47 | 2019 | |
| Pfizer INC. | $86.78 | 2019 | |
| Mylan Specialty L.P. | $37.47 | 2019 | |
| Ge Healthcare | $36.66 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.